Jane Street Group, LLC Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Jane Street Group, LLC

  • $88.2 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 16, 2022
SELL
$20.62 - $37.15 $426,834 - $769,005
-20,700 Closed
0 $0
Q1 2022

May 17, 2022
SELL
$23.5 - $35.38 $744,950 - $1.12 Million
-31,700 Reduced 60.5%
20,700 $725,000
Q4 2021

Feb 15, 2022
SELL
$29.21 - $44.64 $788,670 - $1.21 Million
-27,000 Reduced 34.01%
52,400 $1.7 Million
Q3 2021

Nov 16, 2021
BUY
$21.26 - $38.85 $1.69 Million - $3.08 Million
79,400 New
79,400 $2.34 Million

Others Institutions Holding CERE

# of Institutions
21
Shares Held
5.93M
Call Options Held
27.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email